Drugs / Mepivacaine Injection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05201313 Comparator | Jan → Jul 2022 | vaginal discharge | Azienda Sanitaria-Universitaria Integrata di Udine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mepivacaine Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05201313 ↗ |
| Route | Other | “subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride” NCT05201313 ↗ |
| Route | Subcutaneous | “subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride” NCT05201313 ↗ |